Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618300 | 0.94 | NR3C1 (0.48) | NR3C1TACR1TACR3ALDH1A1KDM4E | |
| SCHEMBL6908693 | 0.88 | NR3C1 (0.45) | NR3C1TACR1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL21465773 | 0.85 | CYP2D6 (0.46) | NR3C1ALDH1A1KDM4ECYP2D6GAA | |
| SCHEMBL12487550 | 0.81 | ABL1 (0.45) | NR3C1ALDH1A1KDM4ECYP2D6LMNA | |
| SCHEMBL5265862 | 0.80 | CYP2D6 (0.44) | NR3C1TACR1TACR3ALDH1A1KDM4E | |
| SCHEMBL5265856 | 0.80 | CYP2D6 (0.44) | NR3C1TACR1TACR3ALDH1A1KDM4E | |
| SCHEMBL5233110 | 0.79 | CYP2D6 (0.43) | NR3C1TACR1TACR3ALDH1A1KDM4E | |
| SCHEMBL5233107 | 0.79 | CYP2D6 (0.43) | NR3C1TACR1TACR3ALDH1A1KDM4E | |
| SCHEMBL2039023 | 0.75 | TACR1 (0.44) | TACR1TACR3ALDH1A1LMNAMEN1 | |
| SCHEMBL191606 | 0.75 | DRD2 (0.59) | ALDH1A1SIGMAR1CYP2D6DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865758-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2536723-B1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| EP-2536723-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2361911-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361911-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011101804-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316163-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | NR3C1 1247/4885TACR1 3160/4885TACR3 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.